Your browser is no longer supported. Please, upgrade your browser.
Settings
NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-13.71 Insider Own0.30% Shs Outstand74.12M Perf Week-15.92%
Market Cap10.37B Forward P/E4.18 EPS next Y32.30 Insider Trans-60.66% Shs Float73.95M Perf Month-41.57%
Income-949.90M PEG- EPS next Q-3.91 Inst Own54.40% Short Float8.21% Perf Quarter-28.58%
Sales1.18B P/S8.78 EPS this Y-32.00% Inst Trans0.51% Short Ratio1.13 Perf Half Y-44.74%
Book/sh10.06 P/B13.42 EPS next Y416.40% ROA-48.20% Target Price264.20 Perf Year54.49%
Cash/sh27.01 P/C5.00 EPS next 5Y0.00% ROE-150.90% 52W Range76.59 - 331.68 Perf YTD21.06%
Dividend- P/FCF17.50 EPS past 5Y9.50% ROI-38.00% 52W High-57.32% Beta1.31
Dividend %- Quick Ratio1.40 Sales past 5Y67.30% Gross Margin- 52W Low84.81% ATR13.60
Employees791 Current Ratio1.40 Sales Q/Q739.40% Oper. Margin-78.80% RSI (14)32.42 Volatility8.24% 8.19%
OptionableYes Debt/Eq0.58 EPS Q/Q- Profit Margin-80.40% Rel Volume1.47 Prev Close134.99
ShortableYes LT Debt/Eq0.45 EarningsNov 04 AMC Payout- Avg Volume5.37M Price141.55
Recom2.20 SMA20-13.33% SMA50-32.17% SMA200-29.12% Volume7,925,276 Change4.86%
May-12-21Downgrade JP Morgan Overweight → Neutral $285 → $161
Dec-14-20Initiated Jefferies Buy $200
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Jul-16-20Reiterated H.C. Wainwright Buy $101 → $132
Jul-08-20Downgrade Ladenburg Thalmann Buy → Neutral $50 → $105
Jun-29-20Reiterated H.C. Wainwright Buy $50 → $101
Jun-29-20Reiterated B. Riley FBR Buy $74 → $106
Jun-05-20Upgrade JP Morgan Underweight → Neutral $46
May-28-20Reiterated B. Riley FBR Buy $53 → $61
May-12-20Reiterated H.C. Wainwright Buy $33 → $50
Apr-30-20Reiterated H.C. Wainwright Buy $24 → $33
Nov-27-19Resumed B. Riley FBR Buy $12
Aug-14-19Reiterated H.C. Wainwright Buy $10 → $17
Feb-28-19Downgrade Piper Jaffray Overweight → Underweight $4.50 → $0.25
Dec-18-18Initiated Ladenburg Thalmann Buy $3
Dec-11-18Initiated Oppenheimer Outperform $4
Nov-26-18Upgrade Piper Jaffray Neutral → Overweight
Sep-21-18Upgrade JP Morgan Underweight → Overweight
Oct-27-21 03:47PM  
03:02PM  
11:18AM  
11:04AM  
09:20AM  
08:51AM  
08:48AM  
08:47AM  
08:30AM  
08:30AM  
06:55AM  
05:52AM  
Oct-26-21 08:00PM  
05:28PM  
01:36PM  
10:51AM  
09:15AM  
07:25AM  
07:00AM  
Oct-25-21 06:00PM  
05:43PM  
05:26PM  
05:25PM  
02:50PM  
02:30PM  
12:10PM  
11:30AM  
10:40AM  
Oct-24-21 10:00AM  
09:17AM  
Oct-22-21 08:00PM  
05:49PM  
05:02PM  
04:48PM  
04:15PM  
04:00PM  
03:49PM  
03:40PM  
03:01PM  
02:30PM  
11:30AM  
11:00AM  
11:00AM  
06:30AM  
06:05AM  
05:52AM  
05:51AM  
Oct-21-21 09:26PM  
07:25PM  
06:01PM  
05:47PM  
05:45PM  
04:03PM  
03:09PM  
12:55PM  
12:21PM  
11:57AM  
10:30AM  
10:20AM  
09:31AM  
09:19AM  
05:55AM  
05:51AM  
Oct-20-21 05:57PM  
05:33PM  
04:54PM  
04:12PM  
03:35PM  
03:21PM  
02:39PM  
02:00PM  
01:58PM  
12:28PM  
12:09PM  
11:27AM  
11:20AM  
10:51AM  
10:40AM  
10:35AM  
10:34AM  
10:30AM  
09:51AM  
09:30AM  
08:57AM  
08:33AM  
06:09AM  
05:44AM  
05:14AM  
05:12AM  
04:45AM  
03:40AM  
Oct-19-21 03:35PM  
Oct-18-21 09:15AM  
Oct-16-21 08:15AM  
Oct-15-21 04:53PM  
04:05PM  
04:05PM  
02:14PM  
10:15AM  
Oct-14-21 02:37PM  
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Glenn Gregory MPresident, R&DOct 19Option Exercise19.088,250157,41012,311Oct 21 05:08 PM
Glenn Gregory MPresident, R&DOct 19Sale165.148,2501,362,4274,061Oct 21 05:08 PM
Glenn Gregory MPresident, R&DOct 15Option Exercise37.901,18344,8325,244Oct 19 05:04 PM
Glenn Gregory MPresident, R&DOct 15Sale170.001,183201,1104,061Oct 19 05:04 PM
Glenn Gregory MPresident, R&DOct 12Option Exercise19.088,250157,41012,311Oct 14 05:16 PM
Glenn Gregory MPresident, R&DOct 12Sale163.188,2501,346,2184,061Oct 14 05:16 PM
Glenn Gregory MPresident, R&DOct 05Option Exercise19.088,250157,41012,311Oct 07 05:18 PM
Glenn Gregory MPresident, R&DOct 05Sale174.418,2501,438,8954,061Oct 07 05:18 PM
Erck Stanley CPresident and CEOOct 04Option Exercise27.4542,8291,175,58366,708Oct 05 05:05 PM
Erck Stanley CPresident and CEOOct 04Sale176.1542,8297,544,19523,879Oct 05 05:05 PM
Herrmann John A IIIEVP, Chief Legal OfficerOct 01Option Exercise19.085,00095,4007,760Oct 05 05:02 PM
Erck Stanley CPresident and CEOOct 01Option Exercise27.1749,0001,331,40072,879Oct 05 05:04 PM
Erck Stanley CPresident and CEOOct 01Sale175.1049,0008,580,06423,879Oct 05 05:04 PM
Herrmann John A IIIEVP, Chief Legal OfficerOct 01Sale174.895,000874,4522,760Oct 05 05:02 PM
Glenn Gregory MPresident, R&DSep 30Sale207.25693143,6224,061Oct 01 05:58 PM
Trizzino JohnEVP, CCO and CBOSep 28Option Exercise19.087,501143,11910,047Sep 29 05:06 PM
Trizzino JohnEVP, CCO and CBOSep 28Sale209.927,5011,574,6372,546Sep 29 05:06 PM
Trizzino JohnEVP, CCO and CBOSep 27Option Exercise19.087,501143,11910,047Sep 29 05:04 PM
Glenn Gregory MPresident, R&DSep 27Option Exercise5.953,46020,5876,144Sep 29 05:08 PM
Trizzino JohnEVP, CCO and CBOSep 27Sale234.617,5011,759,8332,546Sep 29 05:04 PM
Glenn Gregory MPresident, R&DSep 27Sale234.432,083488,3154,061Sep 29 05:08 PM
MOTT DAVID MDirectorSep 23Sale252.9024,9616,312,61640,000Sep 24 05:10 PM
Trizzino JohnEVP, CCO and CBOSep 21Option Exercise19.087,500143,1008,218Sep 22 05:05 PM
Trizzino JohnEVP, CCO and CBOSep 21Sale227.377,5001,705,265718Sep 22 05:05 PM
Trizzino JohnEVP, CCO and CBOSep 20Option Exercise19.087,500143,1008,218Sep 22 05:05 PM
Trizzino JohnEVP, CCO and CBOSep 20Sale227.577,5001,706,748718Sep 22 05:05 PM
Glenn Gregory MPresident, R&DSep 15Option Exercise37.901,18344,8325,244Sep 17 05:08 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 15Option Exercise19.085,00095,4005,706Sep 17 05:11 PM
Glenn Gregory MPresident, R&DSep 15Sale229.341,183271,3044,061Sep 17 05:08 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 15Sale229.445,0001,147,193706Sep 17 05:11 PM
Trizzino JohnEVP, CCO and CBOSep 14Option Exercise19.087,499143,0818,217Sep 15 05:03 PM
Trizzino JohnEVP, CCO and CBOSep 14Sale236.617,4991,774,360718Sep 15 05:03 PM
Trizzino JohnEVP, CCO and CBOSep 13Option Exercise19.087,499143,0818,217Sep 15 05:03 PM
Trizzino JohnEVP, CCO and CBOSep 13Sale235.297,4991,764,433718Sep 15 05:03 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 01Option Exercise19.085,00095,4005,706Sep 03 05:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 01Sale247.975,0001,239,867706Sep 03 05:10 PM
Glenn Gregory MPresident, R&DAug 31Sale239.871,386332,4634,061Sep 01 05:23 PM
Glenn Gregory MPresident, R&DAug 26Option Exercise5.956,92141,1808,228Aug 30 06:16 PM
Glenn Gregory MPresident, R&DAug 26Sale233.924,167974,7404,061Aug 30 06:16 PM
Glenn Gregory MPresident, R&DAug 16Option Exercise40.641,86675,8265,927Aug 18 05:26 PM
Glenn Gregory MPresident, R&DAug 16Sale233.521,866435,7504,061Aug 18 05:26 PM
Herrmann John A IIIEVP, Chief Legal OfficerJul 26Option Exercise14.832,89642,9603,602Jul 28 05:00 PM
Herrmann John A IIIEVP, Chief Legal OfficerJul 26Sale197.742,896572,648706Jul 28 05:00 PM
Glenn Gregory MPresident, R&DJul 20Sale215.432,409518,9822,811Jul 22 05:20 PM
Glenn Gregory MPresident, R&DJul 15Option Exercise13.0810,477137,0068,465Jul 19 07:52 PM
Glenn Gregory MPresident, R&DJul 15Sale179.455,6541,014,5972,811Jul 19 07:52 PM
Erck Stanley CPresident and CEOJul 02Option Exercise80.6652,5594,239,51173,054Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 02Sale215.8952,55911,347,06620,495Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 01Option Exercise61.5952,6203,240,96573,115Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 01Sale212.8852,62011,201,51320,495Jul 06 05:03 PM
Glenn Gregory MPresident, R&DJun 17Sale183.282,411441,8872,811Jun 17 06:17 PM
Glenn Gregory MPresident, R&DJun 15Option Exercise13.1610,535138,6858,527Jun 17 06:17 PM
Glenn Gregory MPresident, R&DJun 15Sale191.425,7161,094,1302,811Jun 17 06:17 PM
EVANS GARY CDirectorJun 01Sale146.5062591,5620Jun 03 05:34 PM
Herrmann John A IIIEVP, Chief Legal OfficerMay 28Option Exercise14.832,89542,9323,170Jun 02 04:59 PM
Herrmann John A IIIEVP, Chief Legal OfficerMay 28Sale149.142,895431,748275Jun 02 04:59 PM
King Rachel K.DirectorMay 19Buy139.6470097,7482,800May 21 05:06 PM
Glenn Gregory MPresident, R&DMay 19Sale142.172,385339,0662,811May 19 05:26 PM
Glenn Gregory MPresident, R&DMay 17Option Exercise13.1610,531138,5778,523May 19 05:26 PM
Glenn Gregory MPresident, R&DMay 17Sale133.985,712765,2672,811May 19 05:26 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 07Sale176.6319033,559287May 07 05:10 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 05Option Exercise14.733,40650,1603,309May 07 05:10 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 05Sale185.463,022560,471287May 07 05:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerApr 30Option Exercise14.822,89542,8923,170May 04 06:03 PM
Herrmann John A IIIEVP, Chief Legal OfficerApr 30Sale239.832,895694,317275May 04 06:03 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 07Sale178.0319134,004287Apr 07 05:09 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 05Option Exercise34.013,404115,7713,308Apr 07 05:09 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 05Sale190.103,021574,292287Apr 07 05:09 PM
Herrmann John A IIIEVP, Chief Legal OfficerMar 26Option Exercise14.822,89442,8863,169Mar 30 06:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerMar 26Sale186.802,894540,609275Mar 30 06:10 PM
YOUNG JAMES FDirectorMar 25Option Exercise8.9647,500425,43857,500Mar 25 06:41 PM
YOUNG JAMES FDirectorMar 23Option Exercise46.0010,000460,00020,000Mar 25 06:41 PM
YOUNG JAMES FDirectorMar 23Sale228.2210,0002,282,23110,000Mar 25 06:41 PM
MCMANUS MICHAEL A JRDirectorMar 19Sale220.784,000883,1105,951Mar 23 05:33 PM
Glenn Gregory MPresident, R&DMar 17Sale218.862,423530,3042,811Mar 17 06:35 PM
Glenn Gregory MPresident, R&DMar 15Option Exercise109.9510,5311,157,8438,523Mar 17 06:35 PM
EVANS GARY CDirectorMar 15Option Exercise19.5224,500478,33040,599Mar 17 06:36 PM
EVANS GARY CDirectorMar 15Sale211.2124,5005,174,53616,099Mar 17 06:36 PM
Glenn Gregory MPresident, R&DMar 15Sale198.605,7121,134,4002,811Mar 17 06:35 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 09Sale168.0919031,937287Mar 09 07:38 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 05Option Exercise14.733,40450,1483,308Mar 09 07:38 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 05Sale163.463,021493,824287Mar 09 07:38 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 26Option Exercise14.822,89542,8923,170Mar 02 05:37 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 26Sale225.482,895652,759275Mar 02 05:37 PM
Glenn Gregory MPresident, R&DFeb 18Sale269.572,434656,1342,811Feb 18 06:59 PM
Glenn Gregory MPresident, R&DFeb 16Option Exercise13.1610,531138,5778,523Feb 18 06:55 PM
Glenn Gregory MPresident, R&DFeb 16Sale282.715,7121,614,8122,811Feb 18 06:55 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 09Sale324.5019462,953287Feb 09 07:40 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 05Option Exercise14.733,40650,1603,309Feb 09 07:40 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 05Sale290.463,022877,766287Feb 09 07:40 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 01Option Exercise18.1515,022272,72415,297Feb 03 05:37 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 01Sale241.5015,0223,627,789275Feb 03 05:37 PM
Trizzino JohnEVP, CMO and CBOJan 07Sale124.1750662,830287Jan 07 07:08 PM
Trizzino JohnEVP, CMO and CBOJan 05Option Exercise18.6313,756256,24317,694Jan 07 07:08 PM
Trizzino JohnEVP, CMO and CBOJan 05Sale112.0017,4071,949,522287Jan 07 07:08 PM
YOUNG JAMES FDirectorDec 31Option Exercise51.2711,000564,00011,000Jan 05 05:38 PM
DOUGLAS RICHARDDirectorDec 31Option Exercise50.001,00050,00028,500Jan 05 05:42 PM
YOUNG JAMES FDirectorDec 31Sale113.0911,0001,244,0140Jan 05 05:38 PM
Erck Stanley CPresident and CEONov 16Option Exercise37.1452,3171,942,80172,811Nov 18 06:09 PM
Erck Stanley CPresident and CEONov 16Sale90.6552,3164,742,66720,495Nov 18 06:09 PM